Navigation Links
YM BioSciences presents CYT387 and CYT997 data at international cancer conference
Date:2/11/2010

events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BioSciences granted two US patents for AeroLEF(R)
2. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
3. YM BioSciences reports second quarter 2010 operational and financial results
4. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
5. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
6. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
7. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
8. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
9. YM BioSciences announces result of Cytopia shareholder vote
10. Profectus Biosciences to Present at Key Investor Conference in January 2010
11. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Proove Biosciences , a commercial ... to announce the launch of Proove Non-Opioid ... 62 genetic variations to predict good versus poor ... non-opioid pain medications, namely ibuprofen (brand name Advil, ... Xanax) and acetaminophen (brand name Tylenol). , ...
(Date:4/23/2015)... Texas (PRWEB) April 23, 2015 ReliantHeart's ... True Flow (blood flow through the device) in real ... by Numerex, the world’s leading provider of Machine to ... , True Flow via VADLink.com can ... there is any drop in flow below a minimum ...
(Date:4/22/2015)... , April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today ... first quarter 2015 on Thursday, May 7, 2015 after ... a webcast and conference call for 4.30 pm ET ... Live audio of the conference call will be ... investors, members of the news media and the general ...
(Date:4/22/2015)... 2015 2015 HIMSS Annual Conference & ... of the 9th annual Venture+ Forum pitch competition for ... selected to deliver live pitch presentations to a panel ... HIMSS15 held last week in Chicago ... professionals and 1,200 exhibiting companies from around the world, ...
Breaking Biology Technology:Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2TowerView Health Named Venture+ Forum Pitch Competition Winner At HIMSS15 2TowerView Health Named Venture+ Forum Pitch Competition Winner At HIMSS15 3
... BUENOS AIRES, Argentina, March 30 The Development Group ... met in the city of Buenos Aires in order ... Criteria." , (Logo: ... document will be formally submitted at the 4th International,Conference ...
... CRANBURY, N.J., March 30 Amicus Therapeutics (Nasdaq: ... Matthew R. Patterson, will be presenting at the upcoming 16th ... Biotech Industry conference at New York City,s Millennium Broadway ... to begin on Thursday, April 2, 2009 at 9:30 a.m. ...
... March 30 InterMune, Inc. (Nasdaq: ITMN ) ... and President of InterMune, will present at Citi,s 4th Annual ... at 10:40 a.m. EDT. To access a live audio ... log on to the investor relations page of InterMune,s corporate ...
Cached Biology Technology:International Soy Experts Meeting in Argentina Called by the Round Table on Responsible Soy Association (RTRS) 2
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... are important vehicles for the transmission of enteric ... including human pathogens, are particularly abundant in bivalve ... procedures, thus representing a potential risk for human ... to affect the persistence of vibrios in these ...
... population of North Pacific right whales, found during the summer ... whale populations in the world. Commercial whaling in the 1800s ... these whales have been recognized as a different species from ... the Southern Hemisphere. , To help define areas and ecological ...
... in northern China starting as far back as 2400 ... farming combined with other crops, says University of Toronto ... with Chinese agriculture, most archeologists have, until recently, thought ... food associated with northern China. However, recent archeological research ...
Cached Biology News:Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host. 2Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska 2